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Abstract
Background: Cancer arises from normal cells through the stepwise accumulation of genetic alterations. Cancer
development can be studied by direct genetic manipulation within experimental models of tumorigenesis.
Thereby, confusion by the genetic heterogeneity of patients can be circumvented. Moreover, identification of the
critical changes that convert a pre-malignant cell into a metastatic, therapy resistant tumor cell, however, is one
necessary step to develop effective and selective anti-cancer drugs. Thus, for the current study a cell culture model
for malignant transformation was used: Primary human fibroblasts of the BJ strain were sequentially transduced
with retroviral vectors encoding the genes for hTERT (cell line BJ-T), simian virus 40 early region (SV40 ER, cell line
BJ-TE) and H-Ras V12 (cell line BJ-TER).
Results: The stepwise malignant transformation of human fibroblasts was analyzed on the protein level by
differential proteome analysis. We observed 39 regulated protein spots and therein identified 67 different proteins.
The strongest change of spot patterns was detected due to integration of SV40 ER. Among the proteins being
significantly regulated during the malignant transformation process well known proliferating cell nuclear antigen
(PCNA) as well as the chaperones mitochondrial heat shock protein 75 kDa (TRAP-1) and heat shock protein HSP90
were identified. Moreover, we find out, that TRAP-1 is already up-regulated by means of SV40 ER expression
instead of H-Ras V12. Furthermore Peroxiredoxin-6 (PRDX6), Annexin A2 (p36), Plasminogen activator inhibitor 2
(PAI-2) and Keratin type II cytoskeletal 7 (CK-7) were identified to be regulated. For some protein candidates we
confirmed our 2D-PAGE results by Western Blot.
Conclusion: These findings give further hints for intriguing interactions between the p16-RB pathway, the
mitochondrial chaperone network and the cytoskeleton. In summary, using a cell culture model for malignant
transformation analyzed with 2D-PAGE, proteome and cellular changes can be related to defined steps of
tumorigenesis.
Introduction
The stepwise accumulation of genetic alterations in nor-
mal cells is estimated to be a major cause of cancer.
One approach to study cancer development is direct
genetic manipulation of primary cells to generate experi-
mental models of tumorigenesis. Traditionally, murine
cells or transgenic mouse models have been the primary
targets of investigation and have provided crucial
insights into the molecular mechanisms underlying can-
cer development [1].
However, cancer biology of murine and human tissues
clearly differs [2]. For example, primary human cells
cannot be transformed with most combinations of onco-
genes that readily induce transformation of primary
rodent cells. In addition, prolonged culture of mouse
embryonic fibroblasts (MEFs) results in their sponta-
neous immortalization, whereas comparable treatment
of human fibroblasts leads to replicative senescence [2].
This phenomenon can be partially attributed to telo-
mere biology: unlike murine embryonic fibroblasts,
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primary human fibroblasts have relatively short telo-
meres and lack detectable telomerase activity.
The majority of human tumor cells are telomerase-
positive and expression of the catalytic subunit of the
telomerase holoenzyme (hTERT) is sufficient to immor-
talize a variety of human primary cell types [3,4]. For
example, SV40 LT transfected human fibroblasts have
an extended lifetime but undergo crisis that can be res-
cued by expression of hTERT. Consistently, Hahn and
co-workers succeeded to transform human primary
fibroblasts and epithelial cells with the classical onco-
genes H-Ras V12 and the transforming early region of
simian virus 40 (SV40 ER) following initial expression of
hTERT in primary cells [5]. Subsequent work from
many laboratories has confirmed the results and used
the same combination of introduced genes to convert a
wide variety of primary human cells to tumor cells,
including human mammary epithelial, airway epithelial,
glial, endothelial and mesothelial cells [6-10].
Whereas induction of hTERT and activating muta-
tions of H-Ras are frequently observed in human
tumors, the small DNA tumor virus SV40 does not
appear to be a common cause of human cancer. How-
ever, a dissection of the signaling pathways affected by
SV40 ER has revealed striking similarities between SV40
ER function and alterations seen in human tumors [11].
The SV40 ER produces two major gene products, the
large tumor antigen (LT) and the small tumor antigen
(ST). LT is known to bind to and modulate the action
of many host cell proteins, however, its role in the
transformation of human cells appears to lie solely in
the inactivation of the two major tumor suppressors,
p53 and RB [11]. Consistently, specific siRNAs directed
against RB and p53 can replace the requirement for LT
in these experiments [12]. In contrast, ST, which inacti-
vates the Serine/threonine-protein phosphatase (PP2A)
via binding to the A and C subunits, exerts its onco-
genic potential, at least partially, by preventing depho-
sphorylation of c-Myc, resulting in c-Myc stabilization
[13-15]. Moreover, a stable c-MycT58A mutant that
cannot be dephosphorylated by PP2A replaces SV40 ST
in human cell transformation and tumorigenesis assays.
Considering that c-Myc is one of the first identified
oncogenes, it can be concluded that the transforming
early region of SV40 appears to target the same cellular
signaling pathways that are frequently affected during
human tumorigenesis. In turn this renders the model of
human cell transformation by the combination of the
defined genetic elements hTERT, SV40 ER and H-Ras
V12 an attractive model system to analyze changes dur-
ing human cell transformation in molecular terms.
Progress in genomic and proteomic technologies (e.g.
sensitive and fast MS and MS/MS analysis of proteins
and peptides) promise to identify the characteristic
signatures of specific cancer subtypes, to improve the
classification of tumor types, and to identify prognosti-
cally relevant markers. However, these studies are always
confounded by the genetic heterogeneity of patients.
Thus, understanding the development of the trans-
formed phenotype therefore requires analysis of the var-
ious stages of tumorigenesis in a defined genetic
background. Whole-genome-scale technology then
allows the identification of the molecular changes during
each transition. As a first approach, we analyzed the
stepwise transformation of human fibroblasts by a pro-
teomic technique. Therefore, human primary fibroblasts
of the BJ strain, that were sequentially transduced with
retroviral vectors encoding the genes for hTERT (BJ-T),
SV40 ER (BJ-TE) and H-Ras V12 (BJ-TER), were used
(Figure 1) [16]. Whereas the mortal BJ fibroblasts enter
replicative senescence after prolonged culture, BJ-T cells
prevent senescence due to expression of active telomer-
ase. BJ-TE cells have disrupted RB- and p53-regulated
checkpoints but remain anchorage-dependent and non-
tumorigenic. In contrast, BJ-TER cells represent a fully
transformed phenotype including tumorigenicity in vivo,
as previously shown [5]. For visualizing different pro-
teomes, two-dimensional polyacrylamide gelelectrophor-
ese (2D-PAGE) is the method of choice [17-19].
Therefore, this technique was used to get an overview of
the proteome of the described cell lines that represent
defined stages of the malignant transformation process.
Our results give new insights in the proteome changes
following the stepwise transformation of human cells.
We present the characterization of 39 distinct differen-
tially regulated protein spots which contain 67 proteins
including PCNA, Peroxiredoxin-6 (PRDX6), Plasmino-
gen activator inhibitor 2 (PAI-2), the cytoskeletal protein
cytokeratin-7 (CK-7) and the cytoskeletal associated pro-
tein Annexin A2 (p36) as well as the heat shock pro-
teins TRAP-1, HSP90-alpha and HSP90-beta.
Materials and methods
Malignant Transformation - Generation of cell lines
The cell lines BJ-T, BJ-TE and BJ-TER (Figure 1) were
generated by sequential infection of the human diploid
fibroblast strain BJ (ATCC CRL-2522) with retroviruses
that were produced by transfection of the amphotropic
packaging cell line PT67 (Becton Dickinson, Heidelberg,
Germany) with the plasmids pWZL-blast3-hTERT,
pZIP-SV776-1 or pLPC-HrasV12 [5,20,21]. Transduced
cells were selected with 1 μg/ml blasticidin (Merck,
Darmstadt, Germany), 400 μg/ml G418 (PAA, Pasching,
Austria), or 0.75 μg/ml puromycin (Becton Dickinson),
respectively. All cell lines were maintained in Dulbecco’s
Modified Eagle’s Medium (Sigma, München, Germany)
supplemented with 10% fetal bovine serum (Sigma), 1%
penicillin G/streptomycin (Invitrogen, Karlsruhe,
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Germany) and 0.4% Amphotericin (Sigma). Media were
changed twice a week and cells were grown in a humidi-
fied atmosphere with 5% CO2.
Sample preparation
Confluent cell plates with a diameter of 12 cm were
washed twice with PBS (Sigma). Next, cells were scraped
from the plate in 2 mL PBS and centrifuged for 10 min
at 400 ×g and 4°C. The resulting pellet was lysed with 7
M urea (AppliChem, Darmstadt), 2 M thiourea (Merck),
2% CHAPS (Merck) supplemented with 1 tablet pro-
tease inhibitor Complete Mini (Roche) per 10 mL buffer.
Subsequently, samples were sonicated six times in an
ultrasonic bath for 10 seconds with cooling intervals of
one minute. Afterwards samples were centrifuged at
16000 ×g for 10 min. The supernatant was stored at
-80°C. The protein amount was determined by Amido
Black assay [22].
2D-PAGE
Immediately before 2D-PAGE separation, 100 μg of pro-
tein samples were diluted with IEF buffer, containing 7
M urea, 2 M thiourea, 2% CHAPS, 5% 2,2’-Dithiodietha-
nol (Sigma) and 2% IPG buffer (GE Healthcare, Munich,
Germany) to a final volume of 100 μL. That way pre-
pared samples were used for 2D-PAGE as described
elsewhere [17]. For the first dimension 24 cm IPG strips
(3-10 NL) (GE Healthcare) and sample cups were used.
Isoelectric focusing was performed for a total of 50 kVh
(hold 150 V for 2 h, hold 300 V for 2 h, ramp to 500 V
in 2 h, ramp to 1000 V in 3 h, ramp to 4000 V in 3 h,
hold at 6000 V for 7 h) using an Ettan IPGphor (GE
Healthcare). After IEF, IPG strips were equilibrated in
two steps each 20 min in 6 M urea, 30% glycine, 2%
SDS, 50 mM Tris HCl, pH 8.8 supplemented with 130
mM DTT and 280 mM iodoacetamide respectively. Sub-
sequently, IPG strips were placed on top of 10% polya-
crylamide gels and Mark 12 (Invitrogen) was used as
molecular weight marker for SDS-PAGE. The second
dimension was carried out using the Ettan DALTSix
(GE Healthcare). At the beginning 5 W/gel were applied
for 30 min and afterwards 17 W/gel or max. 100 W
until the running front reached the end of the glass
plate. Gels were fluorescence stained with RuPBS as
described elsewhere [23,24]. Scanned gels were com-
pared and analyzed with the image analysis software
PDQuest Advanced 8.0.1 (Bio-Rad, Munich, Germany)
with BJ cells taken as control. The intensities of the gels
were normalized and all protein spots exhibiting a mini-
mum regulation by a factor of two were marked for
further manual evaluation. Differential protein spots
were excised, washed and digested [25].
Mass spectrometry and data analysis
Proteins were identified by nano-LC-MS/MS analysis.
The analyses were conducted with either an LTQ XL
Figure 1 Cell culture model for malignant transformation and experimental workflow. The primary human fibroblast cell line BJ was
sequentially transduced with retroviruses encoding hTERT, SV40 ER and H-Ras V12 to generate the fully transformed cell line BJ-TER showing the
characteristics of cancer cells. Five independent biological replicates were analyzed for BJ, BJ-T, BJ-TE and BJ-TER.
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using Xcalibur 2.0.5 and Bioworks 3.3.1 (Thermo-Scien-
tific, Dreieich, Germany), a QStarElite in combination
with AnalystQS 2.0 (Applied Biosystems, Darmstadt,
Germany) or a Qtrap4000 in conjunction with Analyst
1.4.2 (Applied Biosystems). Samples were preconcen-
trated using a Synergi Hydro-RP C18 trapping column
(100 μm ID, 2 cm length, 80 Å pore size, 4 μm particle
size; Phenomenex, Aschaffenburg, Germany) and after-
wards separated on a Synergi Hydro-RP C18 main col-
umn (75 μm ID, 150 mm length, 80 Å pore size, 2 μm
particle size; Phenomenex) using a linear binary gradient
(solvent A: 0.1% formic acid in water; solvent B: 0.1%
formic acid, 84% acetonitril) at a flow rate of 270 nL/
min. Full MS scans from 300 to 1500 or 2000 m/z
respectively were acquired, and the three to five most
intensive peptide ions were subjected to further frag-
mentation, depending on the mass spectrometer. Dupli-
cate detection of a single m/z within 30 s led to
dynamic exclusion.
LTQ raw data-files were converted into mgf-files using
the supplied version of LCQ-DTA.EXE as plug-in to
Mascot Daemon with the following parameters: (a)
minimum mass: 400, (b) maximum mass 3000, (c)
grouping tolerance 1.4, (d) min. scans/group: 1, (e)
intermediate scans: 1, (f) precursor charge: auto. QStar-
Elite and Qtrap4000 wiff-files were converted into mgf-
files using the respective mascot.dll with the parameters:
(a) precursor mass tolerance for grouping 0.05 (QStarE-
lite) 0.2 (Qtrap), (b) max. number cycles between groups
4 (QStarElite) 1 (Qtrap), (c) min. number cycles per
group 1, (d) Remove peaks if intensity < 0.05 (QStarE-
lite) < 0.1 (Qtrap) % of maximum, (e) centroid all MS/
MS data, (f) reject spectra if less than 10 peaks. Protein
identification was performed using Mascot™, Version
2.2.0 (Matrix Science, London, UK) and the SwissProt
database (02-03-2006) with 208005 entries. Mascot para-
meters were choosen as follows: protease: trypsin, fixed
modifications: carbamidomethyl (C), variable modifica-
tions: oxidation (M), taxonomy: Homo sapiens (13538
entries), missed cleavages: 2, peptide and MS/MS toler-
ance: ± 0.2 (QStarElite) ± 0.4 (Qtrap) ± 1.5 (LTQ), sig-
nificance threshold: p < 0.05. For spots not satisfactorily
identified with the SwissProt database an additional
search was conducted against human IPI (version v3.26,
67665 entries) using Mascot™, Version 2.1 (Matrix
Science) with the same parameters used for SwissProt.
Significant MS/MS peptide identifications were verified
manually.
Data interpretation
Hierarchical clustering and visualization of the intensi-
ties of regulated protein spots according to cell line and
regulation pattern was accomplished as described else-
where [26]. Subcellular localization of identified proteins
was extracted from the UniProt database http://www.
uniprot.org/ in December 2009. At the same time func-
tional annotation of the identified proteins was allocated
using the Go Term Mapper website http://go.princeton.
edu/cgi-bin/GOTermMapper and the human GO Slim
categories. Identified proteins were grouped into the
categories for biological process.
Western Blot
Cells pellets, previously flash frozen in liquid nitrogen
and stored at -80°C, were lysed in NP40 buffer (50 mM
Tris-HCl ph 8.0, 150 mM NaCl, 5 mM EDTA ph 8.0,
2% NP40) supplemented with protease inhibitor cocktail
(Roche). 30 μg of soluble protein was separated on 4-
12% NuPAGE Bis-Tris gels (Invitrogen) and transferred
to ECL nitrocellulose membranes by wet blotting. Mem-
branes were blocked with 10% non fat dry milk in TBST
(5 mM Tris, 15 mM NaCl, pH 7.6, 0.1% Tween20). Pri-
mary antibodies were diluted in TBST with 5% non fat
dry milk at the following concentrations: PCNA (sc-56,
Santa Cruz, 1 μg/ml), PRDX6 (ab92322, Abcam),
HSP90-alpha (AB3466, Millipore, 2 μg/ml), HSP90-beta
(AB3468, Millipore, 2 μg/ml), PAI2 (sc-25745, Santa
Cruz, 1 μg/ml), and b-Actin (ab6276, Abcam, 1 μg/ml).
Detection was performed with horseradish peroxidase or
Alexa Fluor 680 linked secondary antibodies using
enhanced chemiluminescence (Thermo Fisher) or infra-
red imaging (Odyssey, LI-COR).
Results
The cell culture model for malignant transformation
consisting of the four cell lines BJ, BJ-T, BJ-TE and BJ-
TER was analyzed by a differential 2D-PAGE approach.
To compare the protein spot patterns of the different
cell lines, a minimum of five cell plates was processed
to obtain five independent biological replicates for each
cell line (gels shown in Additional file 1). Analysis and
subsequent manual validation of the PDQuest output
resulted in 39 differentially regulated protein spots
among the four cell lines. Figure 2 shows a representa-
tive 2D-PAGE gel from cell line BJ and the protein
spots which are regulated among the four cell lines.
To determine which protein spots were regulated by
which genetic alteration, the normalized intensities of
each regulated protein spot were used for hierarchical
clustering. Protein spots were sorted according to their
regulation pattern using the software Cluster [26] and
results are shown in Figure 3. It is evident that many
protein spots show their strongest regulation between
the cell lines BJ-T and BJ-TE caused by the insertion of
SV40 ER. During the malignant transformation from BJ
(via BJ-T and BJ-TE) to BJ-TER the protein spots
become continuously up- or down-regulated except a
few spots. As an example spot 22 shows increased peak
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intensity in stage BJ-T compared to BJ and is absent in
BJ-TE, but up-regulated again due to the H-Ras transi-
tion. Therefore, it may be concluded that the majority
of the regulated proteins during malignant transforma-
tion is either continuously up- or down-regulated.
Moreover, for most protein spots the in-group variabil-
ity is low, indicating good reproducibility. Beside the
visualization of the hierarchical clustering, the number
of spots up-or down-regulated within the transitions is
summarized in Table 1. In addition, spots that were not
detectable before or after a transition are indicated.
Identification of the proteins in differentially regu-
lated 2D-PAGE spots was accomplished by nano-LC-
MS/MS. While 39 protein spots showing significant
changes in intensity, 32 could be readily identified,
corresponding to an identification rate of 82%. More-
over, for 25 protein spots more than a single protein
was identified. Table 2 lists the identified proteins
according to the spot number. Regulation of spot 24
could not be determined, because this protein spot is
absent in the gels of the cell lines BJ and BJ-T. There-
fore the normalized intensities and the error estimated
by PDQuest were included in Table 2 instead. For
more detailed protein information (e.g. MW, pI) also
see the Additional file 1. In total, the analysis of the 39
differential protein spots resulted in the identification
of 67 proteins.
To investigate a relation between the introduction of a
specific genetic alteration and the proteins identified in
the thereby regulated spots in terms of function and
localization, the protein spots were grouped according
to their regulation (as listed in Table 1) and the respec-
tive proteins were further analyzed using UniProt data-
base entries for subcellular localization and the Go
Term Mapper website and human GO Slim categories
for functional annotation. Results are depicted in Figure
4 and Figure 5. Altogether seven proteins were identified
within the six differential protein spots between BJ and
BJ-T cell line, 39 proteins within the 27 spots between
BJ-T and BJ-TE and eight proteins within the four spots
that were differentially expressed between BJ-TE and BJ-
TER. For the multi-step transitions see Table 1. Regard-
ing the subcellular localization (Figure 4), at least a
quarter of the proteins were derived from cytoplasm
during all transitions. In contrast, mitochondrial and
nuclear proteins were mainly involved in the transition
from BJ-T to BJ-TE, whereas proteins localized in the
endoplasmic reticulum were found exclusively in the
multi-step transitions. Moreover, lysosomal and secreted
proteins were not found in the Ras transition. Here it
needs to be mentioned that secreted proteins might
have been lost during cell culture. Moreover, the separa-
tion of membrane proteins by conventional 2D-PAGE is
not sufficient and has to be met by alternative
Figure 2 Proteome visualization of the malignant transformation model cell lines by 2D-PAGE. A representative 2D-gel from the cell line
BJ stained with RuBPS is shown. Regulated protein spots are indicated with arrows and numbers. The degree of regulation for these protein
spots is given in Figure 3, while identified proteins are listed in Table 2.
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separation strategies [27]. Nevertheless, we found some
membrane proteins particularly in the multi-step transi-
tions. Analogous to the subcellular localization, func-
tional classification of the identified proteins was carried
out and the single-step transitions were shown in Figure
5. Compared to the others, in the hTERT transition
fewer amounts of proteins are identified belonging to
the GO slim categories metabolism and biosynthetic
process. In these categories and cell communication the
percentile amount of proteins identified in the H-Ras
transition are increased. Proteins involved in cell death,
multicellular organismal processes and extracellular
structure organization are identified only in the hTERT
and SV40 ER transition. Moreover, introduction of
SV40 ER also affects proteins involved in secretion,
amino acid metabolism, cell differentiation and behavior.
To condense the results found so far, proteins identi-
fied within the regulated spots are displayed in Table 3
according to the transitions and the respective features.
Interestingly, two proteins, Protein phosphatase
methylesterase 1 (PPME1) and Solute carrier family 25
member 24 (SLC25A24), were identified together in the
up-regulated spot 24. Within the same transition (SV40
ER) these proteins were also identified in two different
down-regulated spots.
Summarizing the results, we detected 39 differential
protein spots within the cell culture model for malig-
nant transformation, identified 67 proteins, and grouped
them according to their stage of regulation, localization
and function. One major problem of 2D-PAGE is the
detection of multiple proteins per spot [17], thus a pre-
cise quantification can only be conducted for single-pro-
tein spots. Therefore, in a separate table (Table 4), we
listed the seven spots containing only a single protein,
which was severalfold identified in the replicate gels of
the cell line thereby proving the regulation directly. In
addition, at least three spectra of different peptides were
required for identification to be included into Table 4.
The unambiguously regulated proteins are PRDX6,
PCNA, p36, PAI-2, TRAP-1 and CK-7. In spot 35 two
homologous proteins (HSP90-alpha and HSP90-beta)
were identified. The proteins identified in the other 32
protein spots need to be further validated by other
methods.
Widely known issues of 2D-PAGE are multiple pro-
tein identifications per spot and shifting of proteins in
the 2D-Gel pattern due to modifications. To verify the
expression level for some candidate proteins, Western
Blot analyses were conducted (Figure 6). The Western
Blots of selected proteins confirm that PCNA is up-
regulated due to SV40 ER and PAI2 is most abundant
in cell line BJ-T. The homologous proteins HSP90-alpha
and HSP90-beta detected by 2D-PAGE within spot 35
can be detected separately with Western Blots. Both
HSP90-alpha and HSP90-beta show regulation. Com-
plete HSP90-alpha, HSP90-beta and PRDX6 levels differ
from the regulation pattern of the respective 2D-PAGE
spots, but show the same direction of regulation consid-
ering the full transformation process.
Discussion
A cell culture model for malignant transformation offers
the possibility to study cancer development following
specified genetic alterations in front of a defined genetic
background. During the last decade, 2D-PAGE has been
the standard for separation, visualization and
Figure 3 Hierarchical clustering of intensities of regulated
protein spots according to cell line and regulation pattern. The
five 2D-gel replicates from each cell line are numbered; each
column represents one gel; each row represents a protein spot. The
spot intensities are indicated in grayscale (white = no intensity;
black = highest intensity).
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comparison of closely related proteomes. We decided to
improve the reliability of results by using a minimum of
five cell culture plates from each cell line (Figure 1).
Each plate was processed independently giving at least
five biologically independent recurrences for each cell
line. Only protein spots showing regulation changes
independent of the biological variance are relevant
changes originating from genetic alterations.
Besides gel to gel variation, the choice of the appropri-
ate protein staining method has major influences on the
image analysis with existing software. Commonly, silver
or Coomassie staining is used for the detection of pro-
teins in 2D-gels. Silver staining is a very sensitive protein
visualization method, but suffers from low reproducibil-
ity, because over-staining effects (donut- or crater spots)
and potential interference with subsequent MS occurs
[28,29]. Although colloidal Coomassie staining offers bet-
ter compatibility with MS compared to many silver-stain-
ing protocols, it is less sensitive [30]. To overcome these
limitations we used Ruthenium(II)tris-bathophenanthro-
line disulfonate (RuBPS) [31]. In comparison to silver
staining RuBPS fluorescent staining shows a higher line-
arity in signal intensity and is more reproducible.
Furthermore, RuPBS is more sensitive than Coomassie
and offers compatibility with MS [23,24].
In addition to the use of a MS compatible staining
method the MS method itself has a major effect on the
success of identification. Using nano-LC-MS/MS, we
had an identification rate of 82% in this study. A related
proteomic approach, however, had a rate of roughly 50%
[32], which is most probably due to the use of MALDI-
MS. Moreover, it was previously shown that the use of
MALDI-MS and LC-ESI-MS/MS in combination
achieves the best results [33]. However, superior separa-
tion and sensitivity by nano-LC-MS/MS also led to the
identification of more than a single protein in several
spots - a situation often encountered in 2D-PAGE stu-
dies [17]. The utilized mass analyzers are getting more
sensitive; thus it is possible to identify also very low
abundant proteins in the spots co-migrating in the pre-
sence of high abundant proteins. Although, more than
5000 proteins can be resolved by 2D-PAGE approaches
simultaneously and ~2000 proteins routinely [17],
depending on used gel size and pH gradient. The com-
plexity of complete cell lysates with presumably several
hundred thousand protein features [34] can easily sur-
pass the available resolution. Therefore, the detection of
more than one protein per spot needs to be expected.
In these cases it remains unclear which of the detected
proteins is regulated and other methods need to be
employed for further validation.
Western Blot analysis is a common method to verify
2D-PAGE results regarding the known restrictions: mul-
tiple protein identifications per spot and shifting of pro-
teins in the 2D-gel pattern due to modifications. Our
Western Blots support the findings of 2D-PAGE with
respect to the full transformation process. However, the
2D-PAGE regulation pattern in some cases differs from
the Western Blot results. A possible explanation could
be that in 2D-PAGE single protein species are detected
whereas in Western Blots the total expression level of a
protein including all of its isoforms and modifications is
analyzed.
Besides these technical considerations, many changes
on the proteome level were detected in the malignant
transformation model that are worth to be discussed.
BJ-TE cells have disrupted RB- and p53-regulated
checkpoints but remain anchorage-dependent and non-
tumorigenic. In this step more pathways are altered in a
detectable manner than in the other two steps. SV40 LT
inactivates RB and p53 due to binding of RB via its N-
terminal LXCXE motif and p53 via its bipartite C-
Table 1 Spots regulated within the transitions and the number of identified proteins
transition up-regulated spots sum of up-
regulated
spots
down-regulated spots sum of down-
regulated spots
sum of
identified
proteins
BJ ® BJ-T
(hTERT)
13, 17, 20, 23 4 2, 31 2 7
BJ-T ® BJ-TE
(SV40)
5, 6, 7, 8, 24*, 32 6 1, 2*, 4, 9, 10, 11, 13*, 14, 16, 18, 21, 22*, 23, 25,
26, 28, 29*, 30*, 31, 33, 38*
21 39
BJ-TE ® BJ-TER
(RAS)
22*, 35 2 27*, 31* 2 8
BJ ® BJ-TE
(hTERT + SV40)
5, 6, 7, 8, 17, 19, 24*,
32
8 1, 2*, 4, 9, 10, 11, 12, 13*, 14, 15, 16, 18, 22*, 23,
25, 26, 28, 29*, 30*, 31, 33, 38*, 39
23 48
BJ-T ® BJ-TER
(SV40 + RAS)
3, 5, 7, 8, 19, 24*, 35,
36
8 1, 2*, 4, 9, 10, 11, 13*, 14, 16, 18, 21, 22, 23, 25, 26,
27*, 28, 29*, 30*, 31*, 38*, 39
22 47
BJ ® BJ-TER
(all)
3, 5, 7, 8, 17, 19, 24*,
32, 34, 35, 36, 37
12 1, 2*, 4, 9, 10, 11, 12, 13*, 14, 15, 16, 18, 21, 22, 23,
25, 26, 27*, 28, 29*, 30*, 31*, 33, 38*, 39
25 63
The numbers of spots up- or down-regulated within the transitions are listed and summed up. The number of identified proteins within regulated spots of a
particular transition is presented in the right column. Spots marked with an asterisk are not detectable before or after a transition.
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Table 2 Identified proteins within the protein spots showing at least two-fold up- or down-regulation between the cell
lines of the malignant transformation model
Spot No SwissProt ID gene BJ T TE TER IPI ID
1 P04792 HSPB1 1,00 0,69 0,17 0,13
Q13242 SFRS9
2 P30041 PRDX6 1,00 0,25 0,00 0,00
3 Q06323 PSME1 1,00 0,98 1,03 2,05
P35232 PHB
4 Q9UNF0 PACSIN2 1,00 1,10 0,40 0,34
5 P43487 RANBP1 1,00 0,79 2,18 2,61
P25788 PSMA3
P07686 HEXB
6 Q15691 MAPRE1 1,00 1,03 2,46 1,69
Q99426 TBCB
P61247 RPS3A
7 N.D. 1,00 1,99 5,53 5,98
8 P12004 PCNA 1,00 1,10 2,59 2,97
P01584 IL1B
9 N.D. 1,00 0,88 0,27 0,20
10 N.D. 1,00 0,76 0,21 0,16
11 O00463 TRAF5 1,00 0,71 0,30 0,16
12 P13716 ALAD 1,00 0,72 0,48 0,44
O14656 TOR1A
13 P07355 ANXA2 1,00 2,58 0,00 0,00
14 P31942 HNRPH3 1,00 0,99 0,29 0,18
P02545 LMNA
15 N.D. 1,00 0,62 0,39 0,40
16 N.D. 1,00 0,95 0,41 0,34
17 O60664 M6PRBP1 1,00 2,30 3,26 2,40
P06748 NPM1
P07195 LDHB
18 P08670 VIM 1,00 1,03 0,33 0,23
19 Q9UJZ1 STOML2 1,00 1,24 2,46 2,81
Q9NWT6 HIF1AN
O94905 ERLIN2
20 P05120 SERPINB2 1,00 2,18 1,84 1,50
P60709 ACTB
21 P60709 ACTB 1,00 1,09 0,53 0,38
22 P60709 ACTB 1,00 1,80 0,00 0,39
Q12905 ILF2
P60842 EIF4A1
O60664 M6PRBP1
23 N.D. 1,00 2,14 0,42 0,36
24 Q9Y570 PPME1 0 0 235347 119221
Q6NUK1 SLC25A24 IPI00337494
25 Q9Y570 PPME1 1,00 0,79 0,20 0,16
Q13148 TARDBP
P60709 ACTB
26 P23526 AHCY 1,00 0,85 0,40 0,33
P36507 MAP2K2
none none IPI00410404
Q6NUK1 SLC25A24 IPI00337494
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terminal binding domain [35]. Unlike SV40 LT the exact
contribution of SV40 ST to cellular transformation
remains elusive. It is known that SV40 ST binds PP2A,
stimulates the phosphorylation of Protein Kinase B
(Akt) and affects the c-Myc pathway [13,14].
Besides the transition BJ-T to BJ-TE, the other transi-
tions also significantly affect the proteome as detectable
by 2D-PAGE. A thorough study on the H-Ras transfor-
mation step was done by Young and coworkers who
investigated the proteomic changes associated with
expression of H-Ras in a human ovarian epithelial cell
line that was immortalized with SV40 LT, ST and the
human catalytic subunit of telomerase [32]. They identi-
fied 32 proteins that were up- or down-regulated more
than 1.5 fold. Moreover, they used a narrower pH range
from 4 to 7 resulting in a higher resolution of this part
of the proteome. Proteins detected are involved in cellu-
lar processes like metabolism, redox balance, calcium
signaling, apoptosis and cellular methylation. The unam-
biguously regulated proteins identified in our current
analysis were not detected by their approach. Thus the
cell line reflecting the tissue origin possibly has a major
Table 2 Identified proteins within the protein spots showing at least two-fold up- or down-regulation between the cell
lines of the malignant transformation model (Continued)
27 P06733 ENO1 1,00 1,07 0,57 0,00
P68104 EEF1A1
28 P09913 IFIT2 1,00 0,79 0,06 0,08
P00352 ALDH1A1
Q15813 TBCE
P12268 IMPDH2
O43175 PHGDH
P11413 G6PD
29 P00352 ALDH1A1 1,00 0,71 0,00 0,00
O43175 PHGDH
Q9UMS4 PRPF19
30 P11413 G6PD 1,00 0,74 0,00 0,00
P28838 LAP3
31 N.D. 1,00 0,49 0,23 0,00
32 Q12931 TRAP1 1,00 1,36 3,16 2,15
33 P06396 GSN 1,00 0,88 0,36 0,48
Q96TA1 FAM129B
34 P20591 MX1 1,00 1,78 1,59 2,10
P13667 PDIA4
P11021 HSPA5
P17812 CTPS
35 P08238 HSP90AB1 1,00 0,99 0,97 2,07
P07900 HSP90AA1
36 P30048 PRDX3 1,00 0,94 1,86 2,07
P62491 RAB11A
P27635 RPL10
37 P10809 HSPD1 1,00 1,10 1,79 2,09
P68363 K-ALPHA-1
P07237 P4HB
P60709 ACTB
P54578 USP14
P48643 CCT5
38 P08729 KRT7 1,00 0,96 0,00 0,00
39 Q969P6 TOP1MT 1,00 0,85 0,43 0,38
P08670 VIM
P14625 HSP90B1
Shown are the corresponding SwissProt ID, gene name and the average regulation of the protein spot normalized to the spot intensity in the BJ cells (bold = up-
regulation, bold italic = down-regulation). For detailed information see Additional file 1.
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not yet understood impact on the proteins regulated by
H-Ras.
Cellular localization and function of a list of proteins
point to the ongoing molecular changes (Figure 4 and 5).
Avoiding cell death and apoptosis is an essential step
during malignant transformation. SV40 LT alone
bypasses senescence [36,37], but does not fully immorta-
lize human cells, as such modified cells eventually
undergo crisis. However, in combination with hTERT
immortalization is achieved [11,38]. Thus, finding pro-
teins involved in cell death in the hTERT and SV40 tran-
sition but not in H-Ras transition is not astonishing.
Moreover, our results reflect the finding that human cells
are immortalized by hTERT in combination with SV40
LT. Furthermore, such data-depiction and interpretation
can give a first hint at ongoing molecular changes in an
unknown dataset and enables fast data-access.
Similarly, Table 3 depicts the direct link between
potentially regulated proteins and the respective transi-
tion features. Interestingly, the proteins PPME1 and
SLC25A24 were identified both in the up-regulated spot
24 and within the same transition these proteins were
also identified in two different down-regulated spots
(spot 25 and 26). Thus, they are potentially modified
due to SV40 ER expression and therefore moving in the
2D-gel spot pattern.
Focusing on the seven proteins listed in Table 4,
PCNA is a commonly used proliferation marker.
Within the cell culture model for malignant transfor-
mation higher proliferation is observed due to SV40
ER integration and consequently an up-regulation of
Figure 4 Subcellular localization. Subcellular localization of all proteins identified within the protein spots regulated between BJ and BJ-T cells
(top left), between BJ-T and BJ-TE (top middle) and BJ-TE and BJ-TER (top right). Additionally the localization-data of multi step transitions are
depicted in the lower row. Multiple occurrences per protein were allowed.
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PCNA after this transition was detectable with 2D-
PAGE and reinforced by Western Blot. So the up-
regulation of PCNA confirms the observations on cell
culture growth.
PRDX6 has not been described previously to be regu-
lated due to hTERT and SV40 ER integration. Here, we
show that the integration of hTERT results in a down-
regulation of the PRDX6 spot and the subsequent intro-
duction of SV40 ER results in the complete absence of
this spot. In contrast, Western Blot analysis of PRDX6
shows no difference in abundance between BJ and BJ-T,
but indeed PRDX6 is clearly down-regulated due to
SV40 ER and nearly absent in BJ-TER. However,
another study showed the up-regulation of PRDX6 in
metastatic cells [39] and, moreover, PRDX6 was found
to be up-regulated in sera of many patients with esopha-
geal squamous cell carcinoma [40]. Again, we can only
speculate that the direction of regulation is influenced
Figure 5 Function of proteins. Function of all proteins identified in differential spots. After integration of the genetic elements hTERT
(transition from BJ to BJ-T = black), SV40 ER (transition from BJ-T to BJ-TE = dark gray) and H-Ras (transition from BJ-TE to BJ-TER = light gray).
Nucleic acid metabolism (marked with an asterisk) comprise also nucleobase, nucleoside and nucleotide metabolism. Multiple occurrences were
allowed. The vertical-axis displays the share of all proteins identified within the respective transition.
Table 3 Transition features and the presumably regulated proteins
transition transition feature genes presumably up-regulated proteins genes presumably down-
regulated proteins
BJ ® BJ-T
(hTERT)
prevention of senescence ACTB, ANXA2, LDHB, M6PRBP1, NPM1, SERPINB2 PRDX6
BJ-T ® BJ-TE
(SV40)
proliferation and prevention of
apoptosis
HEXB, IL1B, MAPRE1, PCNA, PPME1, PSMA3, RANBP1,
RPS3A, SLC25A24, TBCB, TRAP1
ACTB, AHCY, ALDH1A1, ANXA2,
EIF4A1,
FAM129B, G6PD, GSN, HNRPH3,
HSPB1,
IFIT2, ILF2, IMPDH2,
IPI00410404,
KRT7, LAP3, LMNA, M6PRBP1,
SFRS9,
MAP2K2, PACSIN2, PHGDH,
PPME1, PRDX6,
PRPF19, SLC25A24, TARDBP,
TBCE, TRAF5, VIM
BJ-TE ® BJ-TER
(RAS)
prevention of anoikis and growth-
factor indepandancy
ACTB, EIF4A1, HSP90AA1, HSP90AB1, ILF2, M6PRBP1 EEF1A1, ENO1
The respective transition features and the genes of proteins identified in the spots up- or down-regulated within the transitions are listed. In one case the
protein ID is listed. PPME1 and SLC25A24 were identified both in the up-regulated spot 24 and within the same transition these proteins were also identified in
two different down-regulated spots. Hence, they are mentioned within the presumably up- and down-regulated proteins of the SV40 ER transition.
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by the genetic background and tissue origin of the cells.
Nevertheless, PRDX6 is involved in the redox regulation
of the cell and may play a role in the regulation of
phospholipid turnover as well as in protection against
oxidative injury [41]. Changes in redox regulation and
pathways appear to be important for tumorigenesis [42]
so that the role of PRDX6 during tumorigenesis should
to be further investigated.
PAI-2 is well documented as an inhibitor of the uroki-
nase-type plasminogen activator [43]. Furthermore, PAI-2
has been shown to carry out a number of intracellular
functions: it can alter gene expression, influence the rate
of cell proliferation and differentiation, and inhibit apopto-
sis independent of urokinase inhibition [44]. The crucial
change caused by the hTERT transition is yet unclear, but
recent findings suggest that the urokinase plasminogen
activator system is causally involved at multiple steps in
cancer progression [45]. Interestingly, the nuclear-located
PAI-2 was shown to bind to RB via its CD-loop [46].
Also, TRAP-1 was reported to interact with RB [47].
TRAP-1 is a chaperone that expresses an ATPase activ-
ity and protects cells from apoptosis by an unknown
mechanism. Possibly, in tumor cells, the up-regulation
of both TRAP-1 in conjunction with HSP90, which both
interact with Cyclophilin-40 (CypD) maintains mito-
chondrial homeostasis and survival of cells. Blocking the
interaction of TRAP-1 and HSP90 with CypD leads to
CypD mediated mitochondrial induced cell death [48].
In addition, Kang et al. found no increase in TRAP-1 as
a result of Ras-transformation. We could support this
finding, because TRAP-1 is already up-regulated by
means of SV40 ER expression (Figure 7). However,
Kang et al. showed HSP90 up-regulation due to Ras-
transformation; this could also be reinforced by our 2D-
PAGE findings: We identified the homologous proteins
HSP90-alpha and HSP90-beta, sharing 87% identity to
each other in spot 35. Western Blot analysis indicates
up-regulation of both HSP90-alpha and HSP90-beta by
SV40 ER. Taken together these results suggest that not
only Ras-transformation but also SV40 ER affects
HSP90 levels.
Table 4 List of all unequivocally identified proteins
spot
no
SwissProt
ID
protein protein
name
abbreviation
gene pI MW BJ T TE TER Subcellular
localization
selection of biological
processes
2 P30041 Peroxiredoxin-6 PRDX6 PRDX6 6,02 24888 1,00 0,25 0,00 0,00 cytoplasm cell redox homeostasis
8 P12004 Proliferating cell
nuclear antigen
PCNA PCNA 4,57 28750 1,00 1,10 2,59 2,97 nucleus cell proliferation
13 P07355 Annexin A2 p36 ANXA2 7,56 38449 1,00 2,58 0,00 0,00 secreted skeletal system
development
20 P05120 Plasminogen
activator inhibitor 2
PAI-2 SERPINB2 5,46 46566 1,00 2,18 1,84 1,50 cytoplasm,
secreted
anti-apoptosis
32 Q12931 Heat shock protein
75 kDa,
mitochondrial
TRAP-1 TRAP1 8,3 80060 1,00 1,36 3,16 2,15 mitochondrial cellular response to
oxidative stress and protein
folding
35 P08238 Heat shock protein
HSP 90-beta
HSP90 HSP90AB1 4,97 83081 cytoplasm protein folding
P07900 Heat shock protein
HSP 90-alpha
HSP86 HSP90AA1 4,94 84490 cytoplasm mitochondrial transport
and protein refolding
38 P08729 Keratin, type II
cytoskeletal 7
CK-7 KRT7 5,23 51418 1,00 0,96 0,00 0,00 cytoplasm,
cytoskeleton
cytoskeleton organization
Shown are SwissProt ID, protein name and abbreviation as well as gene, isoelectric point (pI), molecular weight (MW), regulation, subcellular localization, and a
selection of the biological processes the proteins are involved.
Figure 6 Western Blots. Western Blots showing expression of the
indicated proteins. (PCNA, PAI2, PRDX6, HSP90-alpha and HSP90-
beta) in the four BJ cell lines. b-Actin is shown as a loading control.
Pütz et al. Molecular Cancer 2010, 9:254
http://www.molecular-cancer.com/content/9/1/254
Page 12 of 15
HSP90 is a molecular chaperon that has ATPase
activity. Its client proteins and interaction partners
are several kinases and signaling molecules e.g. Akt,
p53 and Hypoxia-inducible factor 1 alpha. HSP90
occupies a unique nodal role in cellular homeostasis,
overseeing cell proliferation and cell-survival mechan-
isms [48,49].
Surprisingly, HSP90-alpha and HSP90-beta as well as
PCNA were recently identified as binding partners of
p16INK4a [50], suggesting that p16INK4a possibly plays
a central role in several steps of tumorigenesis distinct
from kinase inhibition. Moreover, the same study also
reveals several cytoskeletal proteins as interacting part-
ners of p16INK4a. Some cytoskeletal proteins were iden-
tified within our investigation, especially six in the
transition from BJ-T to BJ-TE. Considering the pro-
found changes in cell morphology in this step, reorgani-
zation of the cytoskeleton appears to be of high
importance. Furthermore, among the seven unequivo-
cally identified proteins the cytoskeletal protein CK-7
and the possibly cytoskeleton-associated protein p36 are
listed. p36 may cross-link plasma membrane phospholi-
pids with actin and the cytoskeleton and might be
involved in exocytosis [51]. Both, p36 and CK-7, protein
spots are regulated in the same manner and are absent
after expression of SV40 ER. In contrast, CK-7 is
described to be up-regulated in several cancers and
tumors e.g. breast cancer [52], transitional cell papillo-
mas and carcinomas [53].
Besides these seven unambiguously identified proteins,
mass spectrometric analysis identified further potentially
regulated proteins. Although these proteins need to be
validated in future experiments, our findings point to
intriguing interactions between the p16-RB pathway, the
mitochondrial chaperone network and the cytoskeleton.
In detail, SV40 LT is known to bind RB and inactivate
the cell cycle inhibitor p16-RB pathway resulting in
increased cell proliferation. In addition, SV40 LT also
caused marked changes in cell morphology and rendered
the cells more stress-resistant (data not shown). Interest-
ingly, we observed an up-regulation of HSP90 and the
RB-interacting protein TRAP-1 (HSP75), which are part
of the same mitochondrial chaperone network. Specific
expression of these chaperones in mitochondria of tumor
cells but not normal cells has been linked to tumor cell
survival by their inhibitory effect on the mitochondrial
permeability transition [48]. While expression of TRAP-1
was stimulated in response to SV40 early region, mito-
chondrial HSP90 was induced by oncogenic Ras [48].
Up-regulation of TRAP-1 and HSP90 is therefore directly
linked to defined genetic alterations and supports a
model of oncogene cooperation in the establishment of
this tumor-survival promoting chaperone network.
Furthermore, HSP90 has also been identified together
with cytoskeletal proteins in immunoprecipitates of the
cell cycle inhibitor p16INK4a suggesting a possible link
between HSP90 up-regulation and the changes in cytos-
keleton dynamics of Ras-transformed cells [50]. The pro-
teomic changes detected in this study therefore provide
further insight into the molecular basis underlying malig-
nant transformation. The presented list of proteins
enables a more detailed analysis of specific proteins and
pathways involved in cancer development. In addition,
the list allows the investigation of other cell lines and
even different types of cancer concerning the abundance
of these proteins. We will therefore further investigate
this model system.
Additional material
Additional file 1: Detailed information on the analysed 2D-gels and
identified proteins. The first page of the Additional_file_1.pdf lists
identified proteins within the protein spots showing at least two-fold up-
or down-regulation between the cell lines of the malignant
transformation model. Shown are the Isoelectric point (pI), molecular
weight (MW), maximal sequence coverage (seq.cov), maximal identified
peptides (ident. peptides), and the maximal score (score) of the proteins.
The regulation of the protein spot relating to BJ and their normalized
standard deviation (±) is specified. Moreover, on the following pages all
2D-Gels of the analysis are shown.
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Akt: Protein kinase B; CK-7: cytokeratin-7; CypD: Cyclophilin-40; DNA:
Deoxyribonucleic acid; DTT: Dithiothreitol; ESI: electrospray ionization; GO:
Gene Ontology; HSP: heat shock protein; hTERT: catalytic subunit of the
telomerase holoenzyme (Telomerase reverse transcriptase); IEF: isoelectric
focusing; IPG: immobilized pH gradient; IPI: international protein index;
iTRAQ: isobaric tag for relative and absolute quantitation; LC: liquid
chromatography; LT: large tumor antigen; MALDI: matrix-assisted laser
Figure 7 3D view of a gel section from all cell lines: TRAP-1 (spot 32) is identified in the spot marked with an asterisk. Representative
single gel sections are selected, that is, those sections closest to the mean of all five gels from one cell line.
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desorption/ionization; MEFs: mouse embryonic fibroblasts; MS: mass
spectrometry; MS/MS: tandem mass spectrometry; MW: molecular weight;
p16INK4a: Cyclin-dependent kinase inhibitor 2A; p36: Annexin A2; p53:
Tumor suppressor p53; PAGE: polyacrylamide gelelectrophorese; 2D-PAGE:
two-dimensional PAGE; PAI-2: Plasminogen activator inhibitor 2; PBS:
phosphate buffered saline; PCNA: proliferating cell nuclear antigen; pI:
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40; SV40 ER: simian virus 40 early region; TRAP-1: mitochondrial heat shock
protein 75 kDa.
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